Women's Health
What Causes Dry Eyes in Perimenopause with Hypothyroidism?
Dry, gritty, burning eyes affect up to 61% of perimenopausal women — yet most eye drops treat the surface while the real drivers are hormonal and metabolic. When hypothyroidism is also in the picture, two distinct physiological disruptions compound each other in ways that make standard ophthalmology advice fall short.
What Causes Dry Eyes in Perimenopause with Hypothyroidism?
Yes, both perimenopause and hypothyroidism independently cause dry eye disease — and when they occur together, the effect is additive, sometimes severe. Declining estrogen reduces tear film stability and meibomian gland function; low thyroid hormone impairs the same glands through a separate pathway. The exception is women with well-optimized thyroid levels and stable estrogen, who rarely develop clinically significant symptoms.
---
Why Hormones Are the Hidden Root Cause of Dry Eyes
Dry eye disease (DED) is not a single condition — it is a failure of the tear film to maintain a stable, protective layer over the ocular surface. The tear film has three layers: a mucin layer from goblet cells, an aqueous layer from the lacrimal gland, and a lipid layer from meibomian glands embedded in the eyelids. Perimenopause and hypothyroidism each disrupt different parts of this architecture.
How Declining Estrogen Destabilizes the Tear Film
Estrogen receptors are expressed on both the lacrimal gland and the meibomian glands. As estrogen fluctuates and ultimately falls during perimenopause, lacrimal gland secretory function declines. A 2003 Women's Health Study analysis of 25,665 postmenopausal women found that hormone use patterns significantly correlated with dry eye prevalence, establishing a clear epidemiological link between sex hormone status and ocular surface health (Schaumberg et al., JAMA Ophthalmology 2001; PMID: 11476878).
Androgen levels — which also fall during perimenopause — matter equally, perhaps more. Androgens regulate meibomian gland lipid secretion. When androgen levels drop, meibomian gland output decreases and the lipid layer of the tear film thins. A thinner lipid layer allows tears to evaporate faster, producing the hallmark burning and grittiness of evaporative dry eye (Sullivan et al., Investigative Ophthalmology & Visual Science 2002; PMID: 11773025).
If you are also managing insomnia alongside perimenopause and hypothyroidism, poor sleep independently worsens inflammatory cytokines that further damage the ocular surface — another reason these symptoms tend to cluster.
How Hypothyroidism Compounds the Problem
The thyroid gland influences virtually every secretory tissue in the body. In hypothyroidism, thyroid hormone deficiency impairs meibomian gland differentiation and reduces the production of lipid-secreting sebaceous cells. A 2021 cross-sectional study found that patients with hypothyroidism had significantly higher OSDI (Ocular Surface Disease Index) scores and lower Schirmer test values compared to euthyroid controls, confirming measurable lacrimal insufficiency even in treated patients with suboptimal TSH (Gürdal et al., European Journal of Ophthalmology 2011; PMID: 20853257).
Hypothyroidism also increases the viscosity of mucus secretions throughout the body, including the mucin layer of the tear film. Thicker, less-mobile mucin does not spread evenly across the cornea, creating dry patches that trigger the burning sensation many women describe as "sand in my eyes."
Thyroid peroxidase antibodies (TPO-Ab) — elevated in Hashimoto's thyroiditis, the most common cause of hypothyroidism in perimenopausal women — appear to cause additional direct lacrimal gland inflammation independent of TSH levels. This means a woman whose TSH is technically "normal" but whose TPO-Ab is high may still experience significant dry eye driven by autoimmune lacrimal tissue damage.
For women dealing with related hormonal symptoms, anxiety during perimenopause with hypothyroidism shares many of the same root drivers and often co-presents with dry eye during the same hormonal transition.
---
The Biomarkers Worth Checking
If you are experiencing dry eyes in perimenopause with hypothyroidism, the following lab panel goes beyond what a routine eye exam will catch:
| Biomarker | Why It Matters | Optimal Range (not just "normal") |
|---|---|---|
| TSH | Primary thyroid function screen | 1.0–2.5 mIU/L for symptom relief |
| Free T4 | Active thyroid hormone conversion | Mid-to-upper half of range |
| Free T3 | Most biologically active form | Upper third of range |
| TPO Antibodies | Autoimmune lacrimal inflammation | <35 IU/mL |
| Estradiol (E2) | Tear film and meibomian support | Context-dependent by cycle phase |
| Total & Free Testosterone | Meibomian gland lipid production | Lower quartile → high DED risk |
| Omega-3 Index | Meibomian gland lipid quality | >8% is protective |
| Vitamin D (25-OH) | Immune modulation, lacrimal function | 50–80 ng/mL |
| CRP (hs) | Ocular surface inflammation | <1.0 mg/L |
Low vitamin D deserves special mention: vitamin D receptors are expressed in the lacrimal gland, and deficiency is independently associated with dry eye severity. For a deeper look at interpreting your vitamin D result, the article on vitamin D blood tests and optimal ranges explains why the standard 20 ng/mL cutoff misses a significant proportion of symptomatic women.
If your hs-CRP is elevated, systemic inflammation is likely amplifying your ocular surface damage — and the root causes of high CRP are worth understanding before defaulting to lubricating drops.
---
Why Stress Makes Dry Eyes Dramatically Worse
Stress is not a vague lifestyle complaint — it has a precise hormonal mechanism that worsens dry eye. Chronic psychological stress elevates cortisol, which suppresses both estrogen receptor sensitivity and thyroid hormone conversion (T4 → T3). The net effect is that a woman who is already hormonally vulnerable during perimenopause experiences further depression of the exact hormones protecting her tear film.
Cortisol also activates the HPA axis in a way that increases pro-inflammatory cytokines (IL-1β, TNF-α) on the ocular surface. A 2012 study using a mouse model of chronic stress demonstrated significant reductions in goblet cell density — the cells responsible for the mucin layer of the tear film — under sustained HPA activation (Luo et al., Investigative Ophthalmology & Visual Science 2012; PMID: 22491409).
Practical approaches that have the most evidence for reducing cortisol in perimenopausal women include:
- Resistance training 3x/week — shown to reduce cortisol AUC and improve estrogen receptor sensitivity
- Diaphragmatic breathing protocols (5 min, 2x/day) — activates vagal tone and blunts HPA response
- Sleep prioritization — even partial sleep restriction raises cortisol the next evening; if waking at 3am is a recurring issue, that nocturnal cortisol spike is directly relevant to your dry eye severity
- Adaptogenic support — covered in the protocol section below
The stress-dry eye connection is real, bidirectional, and often overlooked in clinical settings that treat the eye in isolation from the nervous system.
---
The Clinical Protocol: What Actually Addresses the Root Causes
Lubricating eye drops relieve symptoms; they do not address the underlying hormonal and inflammatory drivers. A root-cause protocol involves several layers:
Layer 1: Thyroid Optimization
If your TSH is above 2.5 mIU/L and you are symptomatic, discuss with your prescriber whether a dose adjustment is appropriate. Many practitioners use a TSH target of 1.0–2.5 mIU/L for symptom resolution in Hashimoto's patients. Selenium — specifically selenomethionine at 200 mcg/day — has the strongest evidence for reducing TPO antibody titers and protecting thyroid tissue from oxidative damage (Toulis et al., Thyroid 2010; PMID: 20883174). This is not a replacement for thyroid hormone replacement therapy, but it is an important adjunct, particularly for the autoimmune component that drives lacrimal gland inflammation.
Layer 2: Meibomian Gland and Lipid Layer Support
Omega-3 supplementation at clinically meaningful doses (at minimum 2g combined EPA+DHA daily) has direct evidence for improving meibomian gland secretion and reducing evaporative dry eye. A randomized controlled trial of 105 patients with DED found that daily omega-3 supplementation significantly improved TBUT (tear break-up time) and Schirmer test scores compared to placebo over 12 weeks (Bhargava et al., Contact Lens & Anterior Eye 2013; PMID: 23218250).
Layer 3: Vitamin D Repletion
Aim for a 25-OH vitamin D level of 50–80 ng/mL. Vitamin D3 supplementation at 2,000–5,000 IU daily, taken with vitamin K2 (MK-7) to support calcium partitioning, is the standard clinical approach. Vitamin K2 matters here because hypothyroid women are at elevated cardiovascular calcification risk, and D3 without K2 can worsen soft-tissue calcium deposition.
Layer 4: Adrenal and Stress Hormone Support
When chronic stress is contributing to HPA dysregulation and compounding hormone deficits, adaptogenic botanicals can help re-calibrate the cortisol response. Ashwagandha (KSM-66, 600 mg/day) has demonstrated in an RCT of 64 adults a statistically significant reduction in serum cortisol, DHEA-S improvement, and subjective stress scores over 60 days (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798). Lower cortisol means less suppression of T4→T3 conversion and less inflammatory cytokine burden on the lacrimal gland.
---
What This Means for Your Formula
The complexity of overlapping perimenopause and hypothyroidism pathways is exactly where a generic supplement stack falls short. Ones uses an AI-driven analysis of your blood work, wearable data, and symptom profile to build a personalized capsule formula from a curated catalog of clinically validated ingredients. For women presenting with the dry eye pattern described in this article, the most relevant Ones ingredients are:
- Omega-3 (EPA/DHA) — dosed to deliver at least 2g combined daily, calibrated against your omega-3 index result. This directly targets meibomian gland lipid quality and ocular surface inflammation, not just cardiovascular risk.
- Vitamin D3 + K2 (MK-7) — paired together in Ones formulas at doses aligned with your baseline 25-OH vitamin D result, addressing the lacrimal gland receptor deficiency and protecting against thyroid-related cardiovascular risk simultaneously.
- Ones Thyroid Support blend — the proprietary Thyroid Support system blend includes selenomethionine at evidence-based doses relevant to TPO antibody reduction, alongside other ingredients that support T4→T3 conversion. Rather than treating dry eyes topically, this addresses the upstream meibomian gland dysfunction caused by inadequate thyroid hormone signaling.
Ones formulas come in 6 or 9-capsule daily plans. The AI selects the plan based on the depth of your findings — so if your bloodwork shows multiple intersecting deficits, the formula adapts accordingly rather than giving you a fixed product that ignores half your picture.
---
Key Takeaways
- Dry eyes in perimenopause with hypothyroidism have two distinct but overlapping hormonal causes: falling estrogen and androgens reduce tear film stability, while thyroid hormone deficiency impairs meibomian gland secretion independently.
- TPO antibodies — not just TSH — can drive lacrimal gland inflammation even when thyroid levels appear "normal" on standard panels.
- Chronic stress worsens dry eye by raising cortisol, suppressing T4→T3 conversion, and increasing pro-inflammatory cytokines on the ocular surface.
- Key biomarkers to request include Free T3, Free T4, TPO-Ab, Estradiol, Total Testosterone, Omega-3 Index, 25-OH Vitamin D, and hs-CRP.
- Omega-3 supplementation (≥2g EPA+DHA/day), selenomethionine (200 mcg), and vitamin D3+K2 repletion have the strongest clinical evidence for addressing the root causes — not just symptoms.
- Lubricating drops provide surface relief but do not correct the hormonal and inflammatory drivers; a root-cause protocol requires addressing thyroid optimization, lipid layer support, and systemic inflammation together.
---
This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting or changing any supplement or medication protocol.